Search Results | MSF Science Portal

Journal Article

|

Research

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, et al.

2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Conference Material

|

Slide Presentation

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N, et al.

2024-05-16 • MSF Scientific Day International 2024

Conference Material

|

Video

Guglielmetti L

2024-05-16 • MSF Scientific Day International 2024

Conference Material

|

Abstract

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N, et al.

2024-05-16 • MSF Scientific Day International 2024

INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...

Conference Material

|

Video

Mairos Ferreira S, Muthengi K, Mohale M, Mokhameleli S, Mathosi L

2024-05-04 • MSF Paediatric Days 2024

Conference Material

|

Abstract

Mairos Ferreira S, Muthengi K, Mohale M, Mokhameleli S, Mathosi L

2024-05-04 • MSF Paediatric Days 2024

BACKGROUND AND OBJECTIVES
This research emerges from Lesotho's diverse landscapes, where children’s stories remain largely unheard in the realm of health policy. The study aims to ha...

Conference Material

|

Slide Presentation

Mairos Ferreira S, Muthengi K, Mohale M, Mokhameleli S, Mathosi L

2024-05-04 • MSF Paediatric Days 2024

Journal Article

|

Research

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A, et al.

2024-01-29 • medRxiv

BACKGROUND

Aft...

Journal Article

|

Protocol

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, et al.

2023-11-30 • Trials

BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...

Conference Material

|

Slide Presentation

endTB Study Group

2023-11-15 • The Union World Conference on Lung Health 2023

Technical Report

|

Evidence Brief

endTB Study Group

2023-11-15

Each year there are approximately 500,000 new cases of multidrug-resistant tuberculosis (MDR-TB) worldwide, but only a tiny fraction is successfully treated. The endTB trial, led by Méde...

Journal Article

|

Review

Bliznashka L, Rattigan SM, Sudfeld CR, Isanaka S

2023-05-01 • JAMA Network Open

IMPORTANCE
Children treated for acute malnutrition remain at increased risk of relapse, infection, and mortality after programmatic recovery. Global guidelines for the management of ...

Journal Article

|

Research

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY, et al.

2023-01-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...

Journal Article

|

Short Report

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S, et al.

2019-11-02 • Clinical Infectious Diseases

Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...

Journal Article

|

Research

Rick F, Niyibizi AA, Shroufi A, Onami K, Steele SJ, et al.

2017-09-06 • PLOS One

Cryptococcal meningitis is one of the leading causes of death among people with HIV in Africa, primarily due to delayed presentation, poor availability and high cost of treatment. Routin...

Journal Article

|

Research

Shroufi A, van Cutsem G, Cambiano V, Bansi-Matharu L, Duncan K, et al.

2019-08-01 • AIDS

BACKGROUND
Many individuals failing first-line antiretroviral therapy (ART) in sub-Saharan Africa never initiate second-line ART or do so after significant delay. For people on ART w...

Journal Article

|

Research

Fajardo E, Metcalf CJ, Piriou E, Gueguen M, Maman D, et al.

2015-06-25 • Bulletin of the World Health Organization

OBJECTIVE
To estimate the proportion of invalid results generated by a CD4+ T-lymphocyte analyser used by Médecins Sans Frontières (MSF) in field projects and identify factors associ...

Journal Article

|

Research

Zachariah R, Ford NP, Philips M, Lynch S, Massaquoi M, et al.

2009-06-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene

Sub-Saharan Africa is facing a crisis in human health resources due to a critical shortage of health workers. The shortage is compounded by a high burden of infectious diseases; emigrati...

Journal Article

|

Protocol

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, et al.

2021-09-25 • Trials

BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...

Protocol

|

Research Protocol

Khan UT, Huerga H, Khan AS, Mitnick CD, Hewison CCH, et al.

2019-08-20 • BMC Infectious Diseases

BACKGROUND
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaqui...

Science Portal

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Empowering transformation: Harnessing child and youth narratives to propel meaningful and sustainable health and well-being in Lesotho

Empowering transformation: Harnessing child and youth narratives to propel meaningful and sustainable health and well-being in Lesotho

Empowering transformation: Harnessing child and youth narratives to propel meaningful and sustainable health and well-being in Lesotho

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

endTB Clinical Trial: Design, efficacy, safety & linezolid dose-reduction randomization results

High-quality evidence on new, all-oral, shortened MDR-TB regimens

Analysis of postdischarge interventions for children treated for moderate or severe wasting, growth faltering or failure, or edema

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: A feasibility study in rural Lesotho

Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure

Errors generated by a point-of-care CD4+ T-lymphocyte analyser: a retrospective observational study in nine countries

Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens